CCND1 amplified bladder cancers may be sensitive to CDK4 inhibitors [46]; ERBB2 amplified tumors may be sensitive to lapatinib, trastuzumab, or T-DM1 [47]; and MDM2 inhibitors are in current clinical development [48]. This evidence concerns the gene MDM2 and urinary bladder carcinoma.